Indaptus Therapeutics Valuation
| INDP Stock | USD 0.78 0 0.13% |
Indaptus Therapeutics is undervalued. Indaptus Therapeutics retains a regular Real Value of $2.69 per share. The prevalent price of the firm is $0.779. Our model calculates the value of Indaptus Therapeutics from evaluating the firm fundamentals such as Shares Owned By Insiders of 42.92 %, return on equity of -1.4, and Return On Asset of -0.74 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Indaptus Therapeutics' valuation include:
Undervalued
Today
Please note that Indaptus Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Indaptus Therapeutics is based on 3 months time horizon. Increasing Indaptus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Indaptus Therapeutics' intrinsic value may or may not be the same as its current market price of 0.78, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.78 | Real 2.69 | Target 8.5 | Hype 0.76 | Naive 0.82 |
The intrinsic value of Indaptus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Indaptus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Indaptus Therapeutics helps investors to forecast how Indaptus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Indaptus Therapeutics more accurately as focusing exclusively on Indaptus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Indaptus Therapeutics' intrinsic value based on its ongoing forecasts of Indaptus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Indaptus Therapeutics' closest peers.
Indaptus Therapeutics Cash |
|
Indaptus Valuation Trend
Indaptus Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Indaptus Therapeutics' financial worth over time. Using both Indaptus Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Indaptus Therapeutics Total Value Analysis
Indaptus Therapeutics is currently forecasted to have valuation of 2.1 M with market capitalization of 11.02 M, debt of 175.05 K, and cash on hands of 33.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Indaptus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.1 M | 11.02 M | 175.05 K | 33.01 M |
Indaptus Therapeutics Asset Utilization
One of the ways to look at asset utilization of Indaptus is to check how much profit was generated for every dollar of assets it reports. Indaptus Therapeutics retains a negative application of resources of -0.74 (percent), losing $0.007382 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Indaptus Therapeutics shows how discouraging it operates for each dollar spent on its resources.Indaptus Therapeutics Ownership Allocation
The market capitalization of Indaptus Therapeutics is $11.02 Million. Indaptus Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Indaptus Therapeutics Profitability Analysis
Net Loss for the year was (15.42 M) with profit before overhead, payroll, taxes, and interest of 0.About Indaptus Therapeutics Valuation
The stock valuation mechanism determines Indaptus Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Indaptus Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Indaptus Therapeutics. We calculate exposure to Indaptus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Indaptus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.5 K | -1.6 K |
Indaptus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Indaptus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 8.4 M |
Indaptus Therapeutics Current Valuation Indicators
Indaptus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Indaptus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Indaptus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Indaptus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Indaptus Therapeutics' worth.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.